Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
alprostadil prostaglandin d2 receptor 2 small molecule NA drugbank Patent ductus arteriosus[MeSHID:D004374]
Maintenance[MeSHID:D008283]
Congenital Heart Defects[MeSHID:D006330]
Neurogenesis[MeSHID:D055495]
Erectile dysfunction[MeSHID:D007172]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Foot[MeSHID:D017719]		 NA approved,investigational agonist
alprostadil prostaglandin e2 receptor ep1 subtype small molecule NA drugbank , DGIDB Patent ductus arteriosus[MeSHID:D004374]
Maintenance[MeSHID:D008283]
Congenital Heart Defects[MeSHID:D006330]
Neurogenesis[MeSHID:D055495]
Erectile dysfunction[MeSHID:D007172]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Foot[MeSHID:D017719]		 2.12 approved,investigational agonist
alprostadil prostaglandin e2 receptor ep2 subtype small molecule NA drugbank , DGIDB Patent ductus arteriosus[MeSHID:D004374]
Maintenance[MeSHID:D008283]
Congenital Heart Defects[MeSHID:D006330]
Neurogenesis[MeSHID:D055495]
Erectile dysfunction[MeSHID:D007172]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Foot[MeSHID:D017719]		 2.42 approved,investigational agonist
alprostadil prostaglandin e2 receptor ep2 NA Successful target TTD , DGIDB Patent ductus arteriosus[MeSHID:D004374]
Maintenance[MeSHID:D008283]
Congenital Heart Defects[MeSHID:D006330]
Neurogenesis[MeSHID:D055495]
Erectile dysfunction[MeSHID:D007172]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Foot[MeSHID:D017719]		 2.42 approved unknown
alprostadil prostaglandin e2 receptor ep2 NA Successful target TTD , DGIDB Patent ductus arteriosus[MeSHID:D004374]
Maintenance[MeSHID:D008283]
Congenital Heart Defects[MeSHID:D006330]
Neurogenesis[MeSHID:D055495]
Erectile dysfunction[MeSHID:D007172]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Foot[MeSHID:D017719]		 2.42 approved agonist
alprostadil thromboxane a2 receptor NA Successful target TTD , DGIDB Patent ductus arteriosus[MeSHID:D004374]
Maintenance[MeSHID:D008283]
Congenital Heart Defects[MeSHID:D006330]
Neurogenesis[MeSHID:D055495]
Erectile dysfunction[MeSHID:D007172]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diabetic Foot[MeSHID:D017719]		 0.2 approved unknown
click here to return to the previous page